Carpe Diem S.R.L.

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease4 trials
• Schizophrenia2 trials

Phase

• Phase 33 trials
• Phase 22 trials

Status

• Recruiting4 trials
• Completed1 trial

Lead sponsor

• Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials
• Boehringer Ingelheim International GmbH1 trial
• Intra-Cellular Therapies Inc.1 trial
• Intra-Cellular Therapies, Inc.1 trial

Running trials

• Recruiting

  A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease

  2024-513035-25-00· Phase 2· Intra-Cellular Therapies Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

  NCT06651567· Phase 2· Intra-Cellular Therapies, Inc.· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease4 recruiting
• Schizophrenia1 recruiting

Closed trials

• Completed

  A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study

  2024-511560-93-00· Phase 3· Boehringer Ingelheim International GmbH· Source